Related posts

Modest Mondaycash, credit and health3 Must Have Safe Stocks to Play Defensive
Investor Insights

This summary was created by AI, based on 22 opinions in the last 12 months.

Merck & Company, with symbol MRK-N, is a pharmaceutical company with a strong focus on oncology drugs, particularly Keytruda. The company has a robust drug pipeline and a good balance sheet, but experts are cautious due to the upcoming patent expirations and the need to replace those sales. However, the company is seen as a reasonable choice in the sector with potential for future growth.

Consensus
Cautious
Valuation
Fair Value
BUY
Merck & Company

Shares jumped today after getting approval for their pulmonary hypertension drug. This is huge. In 2023, 40% of their sales were from the keytruda drug, but this will go off patent in 2028

biotechnology / pharmaceutical
BUY
Merck & Company

Absolutely a reasonable choice in the sector. Beat numbers last quarter. Lots of cash, ability to buy assets in areas of growth or where they want to add expertise. Increased guidance. Worth owning.

biotechnology / pharmaceutical
BUY
Merck & Company

Better pipeline than PFE. Very strong oncology drug, proving effective in cocktail form against different cancers. This one drug represents over 40% of revenues. Patent on this one runs off around 2027-28, but pipeline is robust.

biotechnology / pharmaceutical
DON'T BUY
Merck & Company

He owns ELI and AZN instead. MRK's key drug, Keytruda, is an anti-cancer treatment which drove their sales up 21% last year, and amounts to nearly 30% for their sales, but the patent cliff will happen in 2028. So, MRK must replace those sales (drug pipeline or buy a company). Be cautious here.

biotechnology / pharmaceutical
TOP PICK
Merck & Company

Portfolio of cancer-fighting stars. Great portfolio and great pipeline. Low valuation of 12x earnings. AAA balance sheet, good future. Good times ahead. Yield is 3%.

(Analysts’ price target is $124.26)
biotechnology / pharmaceutical
BUY
Merck & Company

A cheap stock. Their Keytruda drug did very well, perhaps the best-selling drug of all time.

biotechnology / pharmaceutical
BUY
Merck & Company

Upgraded today and he agrees. His #1 healthcare pick this year. A key drug will come off patent in 2028, but they have tons of drugs to replace it. They beat and bottom lines.

biotechnology / pharmaceutical
HOLD
Merck & Company

Healthcare is having a poor year, but they have a tremendous drug pipeline and strong balance sheet.

biotechnology / pharmaceutical
BUY
Merck & Company
Questions about Pfizer

Had great success during the pandemic; their vaccine led. The company just offered growth warnings. He prefers Merck for its better valuation and their key drug Keytruda which makes up 35% of their revenue.

biotechnology / pharmaceutical
WATCH
Merck & Company
PFE vs. MRK

Benefitted from Covid vaccines. Patent expirations in a couple of years. How will they continue to grow? Company is confident in acquisitions and internal R&D. She's looking at it, no decision yet. Cheap multiple, attractive yield. More of a deep value play.

MRK's done relatively better. Drugs going off patent also, but pipeline is a bit better. She's looking at this one too, still assessing.

biotechnology / pharmaceutical
premium

It's a Monthly Gems opinion which is available only for Premium members

Curated by Allan Tong since 2019.
99+ opinions with 4.15 rating.

TOP PICK
Merck & Company

Though shares have jumped in the past month, Merck could be entering a new breakout phase. Stability comes from its low 0.34 beta, strong cash flow and growing earnings. It has beaten its last four quarters. It pays a 2.65% dividend. However, its current PE of 90x is far from its five-year norm of 27.53x as well as its competitors Amgen, Eli Lilly and even Moderna. Clearly, the market is pinning high hopes on this name to trade at this valuation.

biotechnology / pharmaceutical
TOP PICK
Merck & Company

She's overweight the healthcare sector as a whole, to withstand both volatility and a potential recession. Diverse portfolio. Earnings have climbed for years. Gained over 20% in August alone, so could be start of an uptrend. Better-than-expected earnings and sales. Increased guidance. Yield is 2.65%.

(Analysts’ price target is $123.11)
biotechnology / pharmaceutical
BUY
Merck & Company

His homework shows that MRK is an excellent opportunity on pipeline, future growth, earnings, and cashflow. 

biotechnology / pharmaceutical
BUY
Merck & Company

Can do the heavy lifting in your portfolio.

biotechnology / pharmaceutical
TOP PICK
Merck & Company

Excellent company with strong R & D capability.
Trading at good price for long term investors.
AAA balance sheet.
Strong dividend yield with excellent coverage (retained earnings more than 50%).

biotechnology / pharmaceutical
Showing 1 to 15 of 255 entries

Merck & Company(MRK-N) Rating

Ranking : 5 out of 5

Bullish - Buy Signals / Votes : 13

Neutral - Hold Signals / Votes : 2

Bearish - Sell Signals / Votes : 2

Total Signals / Votes : 17

Stockchase rating for Merck & Company is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Merck & Company(MRK-N) Frequently Asked Questions

What is Merck & Company stock symbol?

Merck & Company is a American stock, trading under the symbol MRK-N on the New York Stock Exchange (MRK). It is usually referred to as NYSE:MRK or MRK-N

Is Merck & Company a buy or a sell?

In the last year, 17 stock analysts published opinions about MRK-N. 13 analysts recommended to BUY the stock. 2 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Merck & Company.

Is Merck & Company a good investment or a top pick?

Merck & Company was recommended as a Top Pick by on . Read the latest stock experts ratings for Merck & Company.

Why is Merck & Company stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Merck & Company worth watching?

17 stock analysts on Stockchase covered Merck & Company In the last year. It is a trending stock that is worth watching.

What is Merck & Company stock price?

On 2024-03-27, Merck & Company (MRK-N) stock closed at a price of $131.75.